Compare DexCom, Inc. (DXCM) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs ING Groep NV — how do they compare? DexCom, Inc. trades at $77.95 (market cap $28.06B), while ING Groep NV trades at $32.75 (market cap $94.33B). The key difference: ING Groep NV is far larger — about 3.4× DexCom, Inc.'s market cap, and ING Groep NV pays a 3.8% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | ING | |
|---|---|---|
Market Cap | $28.06B | $94.33B |
Sector | Health | Financials |
52-Week High | $89.53 | $33.31 |
52-Week Low | $54.84 | $22.67 |
Enterprise Value | $27.03B | — |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
ING trades at $32.88, up 0.38% today, with a bullish technical outlook supported by moving averages and positive earnings beats in recent quarters. The stock shows a P/E of 13.36 and net income margin of 27.84%, reflecting solid profitability. Recent news highlights strategic moves like a global subscription banking model and management appointments, while analyst consensus is strongly bullish with 62.5% buy ratings.
The outlook remains positive due to earnings momentum and undervaluation relative to intrinsic value estimates near $34. Key risks include volatile cash flows and macroeconomic pressures on European banks. Upside potential hinges on sustained revenue growth and effective execution of digital initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
